Novel Concepts for HIV Vaccine Vector Design

Alayo, Quazim A.; Provine, Nicholas M.; Penaloza-MacMaster, Pablo

doi:10.1128/msphere.00415-17

Cited by 11 publications

(6 citation statements)

References 149 publications

(168 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The CanSino and Sputnik V vaccines specifically use Ad5, which is the same vector platform used in our studies. Ad5 is among the most well-studied vaccine vectors due, in part, to its extraordinary immunogenicity ( 2 , 26 ). Although SARS-CoV-2 vaccines prevent severe disease and death, they do not always confer durable sterilizing immunity, warranting the further optimization of current vaccine regimens.…”

Section: Discussionmentioning

confidence: 99%

Fractionating a COVID-19 Ad5-vectored vaccine improves virus-specific immunity

et al. 2021

Self Cite

View full text Add to dashboard Cite

SARS-CoV-2 has caused a global pandemic that has infected more than 230 million people worldwide. Although several vaccine candidates have received emergency use authorization (EUA), there is still limited knowledge on how vaccine dosing affects immune responses. We performed mechanistic studies in mice to understand how the priming dose of an adenovirus-based SARS-CoV-2 vaccine affects long-term immunity to SARS-CoV-2. We first primed C57BL/6 mice with an adenovirus serotype 5 vaccine encoding the SARS-CoV-2 spike protein, similar to that used in the CanSino and Sputnik V vaccines. The vaccine prime was administered either at a standard dose or 1000-fold lower dose, followed by a boost with the standard dose four weeks later. Initially, the low dose prime induced lower immune responses relative to the standard dose prime. However, the low dose prime elicited immune responses that were qualitatively superior, and upon boosting, exhibited significantly more potent recall and functional capacity. We also report similar effects with a simian immunodeficiency virus (SIV) vaccine. These findings show an unexpected advantage of fractionating vaccine prime doses, warranting a re-evaluation of vaccine trial protocols for SARS-CoV-2 and other pathogens.

show abstract

Section: Discussionmentioning

confidence: 99%

Fractionating a COVID-19 Ad5-vectored vaccine improves virus-specific immunity

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…The CanSino and Sputnik V vaccines specifically utilize Ad5, which is the same vector platform used in our studies. Ad5 is among the most well-studied vaccine vectors, due in part to its extraordinary immunogenicity ( 5 , 6 ). Although SARS CoV-2 vaccines prevent severe disease and death, they do not always confer sterilizing immunity, warranting further optimization of current vaccine regimens.…”

Section: Discussionmentioning

confidence: 99%

Limiting the priming dose of a SARS CoV-2 vaccine improves virus-specific immunity

Sanchez

Palacio

Dangi

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Since late 2019, SARS-CoV-2 has caused a global pandemic that has infected 128 million people worldwide. Although several vaccine candidates have received emergency use authorization (EUA), there are still a limited number of vaccine doses available. To increase the number of vaccinated individuals, there are ongoing discussions about administering partial vaccine doses, but there is still a paucity of data on how vaccine fractionation affects vaccine-elicited immunity. We performed studies in mice to understand how the priming dose of a SARS CoV-2 vaccine affects long-term immunity to SARS CoV-2. We first primed C57BL/6 mice with an adenovirus-based vaccine encoding SARS CoV-2 spike protein (Ad5-SARS-2 spike), similar to that used in the CanSino and Sputnik V vaccines. This prime was administered either at a low dose (LD) of 106 PFU or at a standard dose (SD) of 109 PFU, followed by a SD boost in all mice four weeks later. As expected, the LD prime induced lower immune responses relative to the SD prime. However, the LD prime elicited immune responses that were qualitatively superior, and upon boosting, mice that were initially primed with a LD exhibited significantly more potent immune responses. Overall, these data demonstrate that limiting the priming dose of a SARS CoV-2 vaccine may confer unexpected benefits. These findings may be useful for improving vaccine availability and for rational vaccine design.

show abstract

“…Viral vectors are the best delivery tools for vaccine development, because they have intrinsic adjuvant capability and unique cellular tropism, and they are able to trigger robust adaptive immune responses. A number of new vectors, including Ad26 (adenovirus serotype 26), Ad35, poxvirus (e.g., canarypox virus-based ALVAC vector), replication competent Ad4, and CMV vectors, are currently being developed ( Table 2 ) [ 120 , 121 , 122 , 123 , 124 ]. However, viral vector vaccine platforms do have some limitations, such as preexisting immunity.…”

Section: Ongoing Clinical and Preclinical Testing Of Hiv Vaccinesmentioning

confidence: 99%

Advances in HIV-1 Vaccine Development

Gao

McKay

Mann

2018

Viruses

View full text Add to dashboard Cite

An efficacious HIV-1 vaccine is regarded as the best way to halt the ongoing HIV-1 epidemic. However, despite significant efforts to develop a safe and effective vaccine, the modestly protective RV144 trial remains the only efficacy trial to provide some level of protection against HIV-1 acquisition. This review will outline the history of HIV vaccine development, novel technologies being applied to HIV vaccinology and immunogen design, as well as the studies that are ongoing to advance our understanding of vaccine-induced immune correlates of protection.

show abstract

Novel Concepts for HIV Vaccine Vector Design

Cited by 11 publications

References 149 publications

Fractionating a COVID-19 Ad5-vectored vaccine improves virus-specific immunity

Fractionating a COVID-19 Ad5-vectored vaccine improves virus-specific immunity

Limiting the priming dose of a SARS CoV-2 vaccine improves virus-specific immunity

Advances in HIV-1 Vaccine Development

Contact Info

Product

Resources

About